Leerink Partnrs Weighs in on Genmab A/S FY2027 Earnings

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Research analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for Genmab A/S in a report released on Monday, September 29th. Leerink Partnrs analyst J. Chang expects that the company will post earnings of $1.13 per share for the year. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. The business had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS.

GMAB has been the topic of a number of other research reports. Wall Street Zen raised Genmab A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 26th. Zacks Research cut shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. HC Wainwright lifted their price target on shares of Genmab A/S from $36.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Truist Financial upped their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Finally, Guggenheim upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price on the stock in a research report on Tuesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $32.12 on Thursday. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $32.24. The business has a 50 day moving average price of $25.64 and a 200 day moving average price of $22.33. The company has a market capitalization of $20.61 billion, a P/E ratio of 16.14, a P/E/G ratio of 1.80 and a beta of 0.98.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GMAB. Headlands Technologies LLC lifted its position in Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after buying an additional 1,464 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the period. CWM LLC lifted its holdings in shares of Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after acquiring an additional 603 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after acquiring an additional 1,070 shares in the last quarter. Finally, AlphaCore Capital LLC purchased a new stake in Genmab A/S during the 2nd quarter worth $44,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.